A carregar...
Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection
Atazanavir (ATV) is a new azapeptide protease inhibitor recently approved and currently used at a fixed dose of either 300 mg once per day (q.d.) in combination with 100 mg ritonavir (RTV) or 400 mg q.d. without boosting. ATV is highly bound to plasma proteins and extensively metabolized by CYP3A4....
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology
2006
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1635184/ https://ncbi.nlm.nih.gov/pubmed/16940065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00098-06 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|